Table 2.

Ongoing regimen before oral semaglutide

	Ongoing	Proposed	p
Number of drug classes used (incl. 0)	1.6 ± 0.9	2.2 ± 0.6	< 0.001
Net change in the number of drugs		1 (0—1)	n.a.
Increased number of drugs (add-on)		2414 (54.3%)	n.a.
Add-on from naïve treatment		425 (9.6%)	n.a.
Unchanged number of drugs (switch)		1714 (38.5%)	n.a.
Reduced number of drug (switch 1 vs > 1)		321 (7.2%)	n.a.
Specific medications
Metformin	3553 (79.9%)	3668 (82.4%)	< 0.001
Metformin alone	1380 (31.0%)	0 (0.0%)	n.a.
Sulfonylurea	649 (14.6%)	112 (2.5%)	< 0.001
Pioglitazone	219 (4.9%)	92 (2.1%)	< 0.001
DPP-4 inhibitors	1108 (24.9%)	13 (0.3%)	< 0.001
GLP1-RA	114 (2.6%)	4449 (100.0%)	n.a.
SGLT-2 inhibitors	929 (20.9%)	939 (21.1%)	0.65
Insulin	412 (9.3%)	299 (6.7%)	< 0.001
Basal insulin	403 (9.1%)	298 (6.7%)	< 0.001
Bolus insulin	79 (1.8%)	10 (0.2%)	< 0.001
Regimen before oral semaglutide
No treatment	425 (9.6%)	0 (0.0%)	n.a.
Oral monotherapy	1583 (35.6%)	521 (11.7%)	< 0.001
Dual oral therapy	1592 (35.8%)	2749 (61.8%)	< 0.001
Triple oral therapy	343 (7.7%)	880 (19.8%)	< 0.001
Injectable GLP1-RA	86 (1.9%)		n.a.
Basal insulin	333 (7.5%)	289 (6.5%)	< 0.001
Bolus insulin	79 (1.8%)	10 (0.2%)	< 0.001